Trials of an experimental treatment are going on at several sites in the US. https://www.centerwatch.com/clinical-trials/listings/84057/molybdenum-cofactor-deficiency-type-a-study-alxn1101-neonates-molybdenum/ On 26 February 2021, the U.S. Food and Drug Administration approved fosdenopterin (Nulibry) for intravenous injection to reduce the risk of death due to<unk>  Type A. Fosdenopterin replaces the missing cyclic pyranopterin monophosphate (cPMP).
Molybdenum cofactor deficiency
Molybdenum deficiency
Boron deficiency 
Mineral deficiency
Chromium deficiency
Fluorine deficiency
Biotin deficiency
Copper deficiency